350 related articles for article (PubMed ID: 26552414)
1. First Oncolytic Viral Therapy for Melanoma.
Poh A
Cancer Discov; 2016 Jan; 6(1):6. PubMed ID: 26552414
[TBL] [Abstract][Full Text] [Related]
2. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
3. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
4. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL
Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272
[TBL] [Abstract][Full Text] [Related]
5. Implementing a Program of Talimogene laherparepvec.
Collichio F; Burke L; Proctor A; Wallack D; Collichio A; Long PK; Ollila DW
Ann Surg Oncol; 2018 Jul; 25(7):1828-1835. PubMed ID: 29417403
[TBL] [Abstract][Full Text] [Related]
6. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
7. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
Johnson DB; Puzanov I; Kelley MC
Immunotherapy; 2015; 7(6):611-9. PubMed ID: 26098919
[TBL] [Abstract][Full Text] [Related]
8. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel LD; Zager JS
Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
[TBL] [Abstract][Full Text] [Related]
9. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
Hoffner B; Iodice GM; Gasal E
Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
Burke EE; Zager JS
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
[TBL] [Abstract][Full Text] [Related]
11. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
13. The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.
Andtbacka RH
Clin Adv Hematol Oncol; 2016 Aug; 14(8):576-9. PubMed ID: 27487099
[No Abstract] [Full Text] [Related]
14. Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
Ott PA; Hodi FS
Clin Cancer Res; 2016 Jul; 22(13):3127-31. PubMed ID: 27146699
[TBL] [Abstract][Full Text] [Related]
15. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
Bommareddy PK; Patel A; Hossain S; Kaufman HL
Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
[TBL] [Abstract][Full Text] [Related]
16. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).
Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555
[TBL] [Abstract][Full Text] [Related]
17. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Virotherapy: A Contest between Apples and Oranges.
Russell SJ; Peng KW
Mol Ther; 2017 May; 25(5):1107-1116. PubMed ID: 28392162
[TBL] [Abstract][Full Text] [Related]
19. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
[TBL] [Abstract][Full Text] [Related]
20. Talimogene laherparepvec (Imlygic) for unresectable melanoma.
Med Lett Drugs Ther; 2016 Jan; 58(1486):8-9. PubMed ID: 26761342
[No Abstract] [Full Text] [Related]
[Next] [New Search]